Featured Post from ChristianaCare

Researchers Discover That Cancer Stem Cell Populations in Colorectal Cancers Are Diverse, Not Uniform

Apr 4, 2023

4 min

Discovery may lead to more precise treatments for advanced colorectal cancer


Researchers at ChristianaCare’s Cawley Center for Translational Cancer Research at the Helen F. Graham Cancer Center & Research Institute have demonstrated for the first time that microRNA (miRNA) expression leads to a diversity of cancer stem cells within a colorectal cancer tumor. This diversity of cancer cells may explain why advanced colorectal cancer is difficult to treat. Study results have been in the Journal of Stem Cell Research and Therapy.


The findings broaden the understanding of how miRNA expression adds to cancer stem cell diversity and may lead to more precise anti-cancer treatments for patients with advanced colorectal cancer. The research builds on prior discoveries by scientists at the Graham Cancer Center about how cancer stem cell activity contributes to the development and spread of colorectal cancer.


“Our research shows — at least in the laboratory — that there are different subpopulations of cancer stem cells in a tumor, and they may be driving the growth of the cancer,” said Principal Investigator Bruce Boman, M.D., Ph.D., MSPH, FACP, medical director of Cancer Genetics and Stem Cell Biology at the Graham Cancer Center. “In one subpopulation of cancer stem cells, its miRNA will shut down the stem cell genes that are expressed in another subpopulation, and vice versa, within the same tumor.”


From left: ChristianaCare researchers Lynn Opdenaker, Ph.D., Brian Osmond, Bruce Boman, M.D., Ph.D., Chi Zhang, Victoria Hunsu, Caroline Facey, Ph.D. Not pictured Victoria Stark, MS.


The study focused on the composition of cancer stem cells within a colorectal cancer cell line (HT29) in the laboratory setting. Researchers evaluated the different cancer stem cell subpopulations that were identified by examining patterns of miRNA expression in each subpopulation and looking for differences. The researchers found that each of the four diverse subpopulations that were studied (ALDH, LRIG1, CD166 and LGR5) had a different miRNA expression or gene signature.


The researchers found that miRNA expression could inhibit the expression of messenger RNA (mRNA), which carries instructions from the DNA to encode specific proteins within cells. Therefore, miRNA, by controlling gene expression, dictate which proteins are contained in the stem cells. The researchers discovered the miRNA that are upregulated in certain cancer stem cell subpopulations are downregulated in other cancer stem cell subpopulations. In this way, differential miRNA expression leads to cancer stem cell heterogeneity within colorectal tumor tissue.


“It’s an early research finding and needs to be followed up with other experiments, but it has clear relevance to the clinic,” Boman said. “The question is: Can you target the miRNA to make cancer more sensitive to certain treatments? Because we know what the current anti-cancer treatments are targeting, we may be able to modulate or manipulate the cancer, so it becomes more sensitive to the treatment.”


Identification of a network of genes regulated by microRNAs in a cancer stem cell subpopulation.



For more than a decade, ChristianaCare’s researchers have contributed to the understanding of the role that cancer stem cells and miRNA expression play in the development and spread of colorectal cancer. This latest finding builds on earlier discoveries that examined a link between two cellular signaling pathways: retinoic acid (RA) signaling and wingless-related integration site (WNT) signaling, which are dysregulated by different gene mutations in colorectal tumors.


The RA signaling pathway induces growth arrest and differentiation of cancer stem cells. Notably, retinoic acid is effective against other types of cancer such as leukemia. The role of the WNT signaling pathway has an opposite effect on tumor growth. The WNT signaling pathway is activated by a mutation in the APC (adenomatous polyposis coli) gene in about 90% of cases of colorectal cancer. In APC mutant tissue, dysregulated miRNA expression may underlie an imbalance between the RA and WNT signaling, which then leads to intratumoral cancer stem cell heterogeneity. Still, this mechanism that may enable the cancer to proliferate could also provide clues on how to more effectively treat cancer.


“If you’ve got an imbalance between these two signaling pathways, then you’ve likely got a growth driver,” Boman said. “The question is: Can you suppress the WNT signaling and enhance the retinoic acid signaling?”


It may be possible to increase the sensitivity of colorectal cancer to retinoic acid-type drugs, and therapeutically shift the balance between different cancer stem cell subpopulations, thereby suppressing cancer growth. More research is needed to determine how targeted cancer therapies containing retinoic acid-type drugs may be made more effective against advanced cancer.


This research will be presented at the annual meeting of the American Association for Cancer Research in Orlando, Florida, April 14-19.


This research project was supported by a grant from the Lisa Dean Moseley Foundation.

Powered by

You might also like...

Check out some other posts from ChristianaCare

1 min

Delaware Statewide Collaboration Expands Physician Pipeline with First‑of‑Its‑Kind Clinical Campus — Expert Commentary Available

Delaware is taking a major step to strengthen its health care workforce. ChristianaCare, Bayhealth and the Philadelphia College of Osteopathic Medicine (PCOM) have announced the Delaware Collaborative Clinical Campus, a first‑in‑the‑region initiative that will expand medical student training opportunities, increase residency placements and build a more sustainable pipeline of physicians committed to caring for Delawareans. This collaboration positions Delaware to attract, train and retain the clinicians our communities depend on — ensuring a stronger, more resilient health care workforce. Brian Levine, M.D., chief academic officer and designated institutional official for ChristianaCare is available for interviews to discuss: What the new clinical campus means for Delaware’s health care future How this collaboration strengthens the physician pipeline The impact on training, recruitment and long‑term retention of physicians in the state

2 min

Brian Levine, M.D., Named Chief Academic Officer and Intellectual Property Administrator

ChristianaCare announced Feb. 12 the promotion of Brian Levine, M.D., to chief academic officer, along with his appointment as intellectual property administrator. He will also continue in his role as designated institutional official. As chief academic officer and leader of ChristianaCare’s Department of Academic Affairs, Levine oversees 38 residency and fellowship programs encompassing 315 residents and fellows, along with the education and training of students across the continuum of medical education. He leads the continued growth and strengthening of ChristianaCare’s undergraduate and graduate medical education infrastructure, ensuring that ChristianaCare continues to prepare physicians to care for our community well into the future. In addition, Levine oversees physician assistant education and allied health educational programming, supporting workforce development and long-term community health needs. As the largest academic medical center between Philadelphia and Baltimore, ChristianaCare has been a hub of academic excellence for over a century. ChristianaCare is one of the largest community-based teaching hospital systems in the United States. ChristianaCare also serves as the Delaware Branch Campus for Sidney Kimmel Medical College and the Philadelphia College of Osteopathic Medicine. This unique program allows medical students to complete their third and fourth years of clinical rotations exclusively at ChristianaCare, providing a clear pathway to launch their medical careers in Delaware. Each year, 55 students participate in the Branch Campus program, with many continuing into ChristianaCare’s highly sought-after residency programs and remaining in Delaware to serve local communities. ChristianaCare is a destination of choice for medical students and residents because of its strong patient-centered culture, reputation for excellence, and diversity of clinical experiences that include urban and suburban campuses with a wide range of pathologies. In his newly expanded role as intellectual property administrator, Levine manages and enforces ChristianaCare’s intellectual property policy, ensuring fair and consistent application in alignment with applicable laws and regulations. He also leads the multidisciplinary committee responsible for guiding organizational decisions related to intellectual property valuation, commercialization strategies and revenue distribution. Levine brings deep experience in academic medicine, health system education and scholarly publishing to these responsibilities. An emergency physician, he led the development of widely used clinical reference guides published by the Emergency Medicine Residents’ Association. These pocket-sized tools — covering topics such as antibiotic stewardship, orthopedic injury management, and EKG interpretation — are used by thousands of emergency medicine residents worldwide. Levine has held leadership roles at ChristianaCare for nearly two decades. Since 2018, he has served as associate chief academic officer and designated institutional official. Previously, he was program director of the Emergency Medicine Residency program from 2012 to 2018 and associate program director from 2006 to 2012. Levine is a clinical professor of Emergency Medicine at Sidney Kimmel Medical College at Thomas Jefferson University and previously served as associate medical director for the LifeNet aeromedical transport program. He earned his medical degree from the University of Vermont Larner College of Medicine and completed his emergency medicine residency at ChristianaCare.

3 min

ChristianaCare Plans to Build Health Campus in Georgetown, Delaware

At a time when there is uncertainty about the future of heath care in the U.S., ChristianaCare is doubling down on its investments to expand access to care in Delaware. As part of $865 million in new investments in Delaware over three years that ChristianaCare announced last July, ChristianaCare today submitted a Notice of Intent to the Delaware Health Resources Board to develop a new health campus in Georgetown. The proposed campus will bring more comprehensive care closer to home for residents of Sussex County, an area experiencing rapid population growth and long-standing gaps in access to essential health services. Designed to Meet the Needs of a Growing Community Similar to ChristianaCare’s West Grove Campus in southern Chester County, Pennsylvania, and its upcoming campuses in Springfield and Aston in Delaware County, the new campus will feature a health center offering primary care, specialty care, behavioral health and other outpatient services and a neighborhood hospital with eight emergency beds and eight inpatient beds. This facility is designed to make it easier for residents to receive timely, high-quality care in their own community. “Sussex county is home to a growing and aging population and is designated by the Health Resources & Services Administration (HRSA) as a Medically Underserved Area,” said Janice E. Nevin, M.D., MPH, president and CEO of ChristianaCare. “This new campus will help close gaps in access by bringing high-quality, equitable and more convenient care directly into the community that needs it most. Our goal is simple: ensure that every Delawarean can access the care they need, in the right place at the right time.” Expanding Access While Strengthening Regional Care This new ChristianaCare campus will add local outpatient care, emergency and inpatient care, creating a closer network of services connecting residents to advanced specialty care at ChristianaCare’s regional hospitals. ChristianaCare is partnering with Emerus Holdings, Inc. with respect to the neighborhood hospital component. Emerus is the nation’s leading developer of this care delivery model, partnering in the operation of more than 45 acute care facilities nationwide. This partnership reflects ChristianaCare’s commitment to bringing nationally recognized, high-quality care to Delaware. “We are proud to continue our partnership with ChristianaCare to bring sustainable, compassionate and high-quality health care to the residents of Sussex County,” said Vic Schmerbeck, CEO of Emerus Holdings Inc. “Together, we are building a next-generation model of care designed around the needs of the community—today and for the future.” The 42,000-square-foot Georgetown campus is expected to open in late 2028. The campus is planned for 20769 DuPont Boulevard in Georgetown. The campus is estimated to cost $65.1 million. Planning for Today’s Demand and Tomorrow’s Growth ChristianaCare already offers a range of services in Sussex County—including primary care, specialty care, virtual care and home health and hospice services. However, Sussex and Kent counties are projected to see an 8% population increase by 2030, with a significant rise in residents age 65 and older. As demand for emergency, primary and specialty care grows, this new campus is designed to make care more local, more connected and more responsive to community needs. In addition, ChristianaCare will continue to explore opportunities to expand access to care in other areas of Delaware, including in Kent County.

View all posts
Powered by